All In Biotech

Drug Trial Radar · NCT05707208

A Randomized, Controlled Study of Repeat Dose Sustained Release Lidocaine for Treatment of Chronic Scrotal Pain

A Randomized, Controlled Phase II Study of Repeat Dose ST-01 (Lidocaine Polymer Solution) vs Lidocaine for Spermatic Cord Block in Men With Chronic Scrotal Content Pain

Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

63

Actual

Start

Mar 21, 2023

Primary completion

Dec 4, 2025

Study completion Jan 21, 2026

Sponsor

Lead sponsor
Sustained Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jan 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multi-center, phase 2, randomized, single-blind, three-arm, active-controlled study is comparing repeat doses, every 28 days, of standard of care (SOC) plus ST-01 against SOC plus 1% lidocaine HCL in men experiencing chronic scrotal content pain (CSCP). The main purpose of this study is to determine if repeat injections of ST-01 are safe and effective in reducing pain. After completing a screening phase participants will be randomized into one of three groups: 1) ST-01 70 mg/mL arm, 2) ST-01 140 mg/mL arm, 3) 1% Lidocaine HCL arm (Control). Participants may receive up to 4 study treatment injections given at a minimum of 28-day intervals. Participants randomized to the Control arm will be given the opportunity to cross over to an ST-01 treatment arm after 2 study treatments.

Conditions

  • Chronic Pain

Interventions

  • ST-01Drug

    A sustained release lidocaine formulation designed for the treatment of acute and chronic pain.

  • 1% Lidocaine HCLDrug

    Currently approved lidocaine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Pain Scores on the Numerical Rating Scale (NRS) at 56 days.Time frame: 28 days after the second injection of ST-01 or 56 days after the first injection if only one study injection is received.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Prostate Cancer Centre - Rockyview Hospital

    Calgary, Alberta, Canada

  • Kelowna General Hospital Clinical Research Department

    Kelowna, British Columbia, Canada

  • Vancouver Prostate Centre

    Vancouver, British Columbia, Canada

  • Men's Health Clinic Manitoba

    Winnipeg, Manitoba, Canada

  • Jonathan Giddens Medicine Professional Corporation

    Brampton, Ontario, Canada

  • The Fe/Male Health Centre

    Oakville, Ontario, Canada

  • Mount Sinai Hospital - Men's Health Institute

    Toronto, Ontario, Canada

  • THEO Medical

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.